Marshall Wace is a hedge fund manager that primarily focuses on quantitative, systematic, and fundamental investment strategies, specializing in long/short equity. The firm also engages in venture capital, particularly in privately owned healthcare companies nearing public flotation, and utilizes its proprietary "Trade Optimized Portfolio System" (TOPS) to analyze vast data and crowdsourced investment ideas.
52% of their portfolio is in Biotech & Life Sciences. Deal activity decreased year-over-year (2 deals in the last 12 months vs 8 prior). Average disclosed round size is $177.9M (across 23 rounds with reported amounts).
Portfolio
23
Fund Size
—
Top Stage
Series C
Last 12 Mo
2
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
23 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 Third Arc Bio Inc. | Series A | $52M | Feb 2026 |
 Veradermics | Series C | $150M | Oct 2025 |
 Attovia Therapeutics | Series C | $90M | Apr 2025 |
 35Pharma Inc. | Series C | $53M | Nov 2024 |
 Elektrofi, Inc. | Series C | $112.3M | Oct 2024 |
 Evommune, Inc. | Series C | $115M | Oct 2024 |
 Pathalys Pharma, Inc. | Series B | $105M | Aug 2024 |
 Human Interest | Series E | $267M | Jul 2024 |
 Lycia Therapeutics, Inc. | Series C | $106.6M | May 2024 |
| Attovia Therapeutics | Series B | $105M | May 2024 |
| OOnCusp Therapeutics | Series A | $100M | Jan 2024 |
 BlueWhale Bio, Inc. | Seed | $18M | Sep 2023 |
 Thunes | Series C | $72M | Jul 2023 |
 ConsenSys | Series D | $450M | Mar 2022 |
 Tipalti | Series F | $270M | Dec 2021 |
 TRM Labs | Series B | $60M | Dec 2021 |
 Varo | Series E | $510M | Sep 2021 |
 Varo Bank | Series E | $510M | Sep 2021 |
 InBrace | Series D | $102M | Sep 2021 |
 Pine Labs | Growth | $285M | May 2021 |
 Century Therapeutics | Series C | $160M | Mar 2021 |
 Ripple | Unknown | $200M | — |
 Aviceda Therapeutics | Series C | $199.6M | — |
Top Co-Investors
Logos Capital5 shared
Lone Pine Capital3 shared
Deep Track Capital3 shared
Novo Holdings3 shared
venBio3 shared
OrbiMed3 shared
Catalio Capital Management3 shared
Janus Henderson Investors3 shared
RA Capital Management3 shared
Eldridge2 shared
Warburg Pincus2 shared
The Rise Fund2 shared
Goldman Sachs Alternatives2 shared
Cormorant Asset Management2 shared
BlackRock2 shared
Vivo Capital2 shared
Temasek Holdings2 shared
Visa2 shared
B Capital2 shared
Bessemer Venture Partners2 shared
Last updated: 16 April 2026